Literature DB >> 7564789

Role of thrombin in pulmonary fibrosis.

N A Hernández-Rodríguez1, A D Cambrey, N K Harrison, R C Chambers, A J Gray, A M Southcott, R M duBois, C M Black, M F Scully, R J McAnulty.   

Abstract

Pulmonary fibrosis commonly develops in systemic sclerosis. We assessed the role of thrombin in promoting fibroblast proliferation in the lungs in this disorder. Bronchoalveolar lavage fluid (BALF) thrombin concentrations were higher in ten patients with systemic sclerosis than in 12 healthy controls (14.6 vs 3.6 nmol/L, p < 0.02), but values in patients with cryptogenic fibrosing alveolitis (n = 10) or sarcoidosis (n = 10) were not increased. BALF from all patients induced fibroblast proliferation. This proliferation was attenuated by thrombin inhibitors for BALF from systemic sclerosis patients only. We suggest thrombin contributes to lung fibroblast proliferation in this disorder.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7564789     DOI: 10.1016/s0140-6736(95)91744-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  37 in total

Review 1.  Lung fibrosis.

Authors:  C Fonseca; D Abraham; C M Black
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Protease-activated receptor-2 induces myofibroblast differentiation and tissue factor up-regulation during bleomycin-induced lung injury: potential role in pulmonary fibrosis.

Authors:  Keren Borensztajn; Paul Bresser; Chris van der Loos; Ilze Bot; Bernt van den Blink; Michael A den Bakker; Joost Daalhuisen; Angelique P Groot; Maikel P Peppelenbosch; Jan H von der Thüsen; C Arnold Spek
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

Review 3.  Risk of venous thromboembolism in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.

Authors:  Boonphiphop Boonpheng; Patompong Ungprasert
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

4.  Anticytokine approaches in pulmonary fibrosis: bringing factors into focus.

Authors:  R K Coker; G J Laurent
Journal:  Thorax       Date:  1997-03       Impact factor: 9.139

5.  Serpine2 deficiency results in lung lymphocyte accumulation and bronchus-associated lymphoid tissue formation.

Authors:  Siva Kumar Solleti; Sorachai Srisuma; Soumyaroop Bhattacharya; Javier Rangel-Moreno; Kaiser M Bijli; Troy D Randall; Arshad Rahman; Thomas J Mariani
Journal:  FASEB J       Date:  2016-04-08       Impact factor: 5.191

6.  Rationale for anticoagulant therapy of pulmonary fibrosis.

Authors:  Galina S Bogatkevich; Paul J Nietert; Richard M Silver; Kristin B Highland
Journal:  Am J Respir Crit Care Med       Date:  2014-02-01       Impact factor: 21.405

Review 7.  Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease.

Authors:  Tanjina Akter; Richard M Silver; Galina S Bogatkevich
Journal:  Curr Rheumatol Rep       Date:  2014-04       Impact factor: 4.592

Review 8.  Progress in the understanding of protease-activated receptors.

Authors:  Esteban C Gabazza; Osamu Taguchi; Haruhito Kamada; Tatsuya Hayashi; Yukihiko Adachi; Koji Suzuki
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

9.  A review of current and novel therapies for idiopathic pulmonary fibrosis.

Authors:  Rokhsara Rafii; Maya M Juarez; Timothy E Albertson; Andrew L Chan
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

10.  Short course dexamethasone treatment following injury inhibits bleomycin induced fibrosis in rats.

Authors:  W A Dik; R J McAnulty; M A Versnel; B A E Naber; L J I Zimmermann; G J Laurent; S E Mutsaers
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.